GH Research, Blends, All

CJC/IPA BLEND

$80.00

Bundle & Save

Single

$80.00

per bottle

—

3+ Bottles

per bottle

5% off

Title	Quantity	Discount
Discount	1 - 3	0% $80.00
Discount	4 - 5	5% $76.00
Discount	6 - 7	8% $73.60
Discount	8 +	10% $72.00

Title	Quantity	Discount
Discount	1 - 3	0% $80.00
Discount	4 - 5	5% $76.00
Discount	6 - 7	8% $73.60
Discount	8 +	10% $72.00

Description

CJC-1295 No DAC / Ipamorelin is a dual-peptide research blend designed for laboratory investigation of growth hormone axis pathway models. CJC-1295 No DAC is studied as a GHRH analog model, while Ipamorelin is studied as a ghrelin receptor-associated growth hormone secretagogue model. Together, this blend supports preclinical research into pituitary signaling, GH-axis interaction, IGF-1-associated response, and endocrine pathway modeling.

This compound is intended strictly for in vitro and preclinical laboratory research.

Specifications

Product Classification: Research-Use-Only (RUO)
Total Content: 5 mg CJC-1295 No DAC and 5 mg Ipamorelin lyophilized powder per vial
Compound: CJC-1295 No DAC and Ipamorelin peptide blend
Form: Sterile lyophilized peptide blend
Purity: ≥99%
Storage: Store at −20 °C, protected from light
Packaging: Glass vial in protective sleeve

Applications

Intended for preclinical laboratory research only, including:
• GHRH receptor pathway research
• Ghrelin receptor-associated signaling studies
• Growth hormone axis pathway models
• Pituitary signaling experiments
• IGF-1-associated pathway analysis
• GH secretagogue blend research
• Comparative endocrine peptide studies

Warning

Not for human or animal use. For research purposes only.

Scientific Report

Abstract

CJC-1295 No DAC and Ipamorelin are peptide research compounds studied for complementary roles in growth hormone axis pathway modeling. CJC-1295 No DAC supports GHRH receptor research, while Ipamorelin supports ghrelin receptor-associated secretagogue pathway research. This blend is designed for laboratory investigation into endocrine signaling, pituitary response, GH-axis pathway interaction, IGF-1-associated signaling, and downstream cellular response models.

Mechanistic Pathway

CJC-1295 No DAC / Ipamorelin is designed around combined GHRH and ghrelin receptor-associated pathway modeling.

CJC-1295 No DAC Pathway

Supports research into GHRH receptor signaling
• Used in pituitary pathway models
• Studied for GH-axis response research

Effect: Provides a model for GHRH receptor-associated activity.

Ipamorelin Pathway

Supports research into ghrelin receptor-associated signaling
• Used in growth hormone secretagogue models
• Helps study endocrine pathway response

Effect: Enables research into GHSR-associated secretagogue activity.

Combined GH-Axis Pathway

Supports research into complementary GH-axis signaling
• Used in peptide blend interaction models
• Helps evaluate downstream IGF-1-associated response

Effect: Provides a dual-pathway model for endocrine signaling research.

Pharmacokinetics / Research Profile

Compound	Pathway	Research Notes
CJC-1295 No DAC / Ipamorelin	GHRH receptor / GHSR / GH axis	Dual-peptide model for endocrine pathway research

Dosing Models in Research

Used only in controlled in vitro and preclinical research models to study receptor signaling and endocrine pathway response. No human or animal-use instructions are provided.

Preclinical Research Highlights

Studied as a dual GH-axis research blend
• Used in GHRH and ghrelin receptor-associated pathway models
• Supports pituitary signaling and endocrine response research
• Relevant to IGF-1-associated downstream pathway studies
• Useful for comparative GH secretagogue blend research

Conclusion

CJC-1295 No DAC / Ipamorelin provides a research-use-only model for studying combined GHRH receptor and ghrelin receptor-associated signaling. Its dual-pathway profile supports laboratory research into pituitary response, GH-axis signaling, IGF-1-associated pathways, and endocrine peptide interaction models.